Baricitinib versus placebo or adalimumab in rheumatoid arthritis
<h4>Background</h4> <p>Baricitinib is an oral, reversible, JAK1/JAK2 inhibitor that may have therapeutic value in patients with rheumatoid arthritis.</p> <h4>Methods</h4> <p>In this 52-week, phase 3, double-blind, placebo and active-controlled study, 1307 p...
主要な著者: | Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y |
---|---|
フォーマット: | Journal article |
出版事項: |
Massachusetts Medical Society
2017
|
類似資料
-
Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM
著者:: Taylor, P, 等
出版事項: (2016) -
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
著者:: Keystone, E, 等
出版事項: (2017) -
Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
著者:: Taylor, P, 等
出版事項: (2017) -
Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
著者:: Emery, P, 等
出版事項: (2017) -
Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
著者:: Taylor, P, 等
出版事項: (2016)